Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 1.00 |
| ▸ | FABP1 | P07148 | 1/20 | 0.88 |
| ▸ | FABP6 | P51161 | 1/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.82 |
| ▸ | NPC1 | O15118 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | NOS1 | P29475 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351380 | 1.00 | CXCR4 (1.00) | CXCR4FABP1FABP6KDM4ENPC1 | |
| SCHEMBL10055030 | 0.94 | CXCR4 (0.89) | CXCR4FABP1FABP6KDM4ENPC1 | |
| SCHEMBL29664808 | 0.94 | FABP1 (1.00) | CXCR4FABP1FABP6KDM4ENPC1 | |
| SCHEMBL2230559 | 0.94 | FABP1 (1.00) | CXCR4FABP1FABP6KDM4ENPC1 | |
| Hydrochloric Acid SCHEMBL4696844 | 0.92 | FABP1 (0.96) | CXCR4FABP1FABP6KDM4ENPC1 | |
| SCHEMBL27585010 | 0.92 | FABP1 (0.96) | CXCR4FABP1FABP6KDM4ENPC1 | |
| Fluoride SCHEMBL28270594 | 0.92 | FABP1 (0.96) | CXCR4FABP1FABP6KDM4ENPC1 | |
| SCHEMBL7567775 | 0.91 | CXCR4 (0.82) | CXCR4FABP1FABP6KDM4ENPC1 | |
| SCHEMBL4064838 | 0.91 | CXCR4 (0.82) | CXCR4FABP1FABP6KDM4ENPC1 | |
| SCHEMBL5025381 | 0.91 | CXCR4 (0.82) | CXCR4FABP1FABP6KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025202445-A2 | CXCR4 INHIBITOR COMPOUND IN THE TREATMENT AND/OR THE PREVENTION OF SEVERE ARDS | 4LIVING BIOTECH (FR) | 2025-10-02 | — | — | WO | disclosed |
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
| US-11285151-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210401836-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | EMORY UNIVERSITY (US) | 2021-12-30 | — | — | US | disclosed |
| US-20210401836-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | EMORY UNIVERSITY (US) | 2021-12-30 | — | — | US | disclosed |
| US-10813911-B2 | Methods of treating and/or preventing chronic obstructive pulmonary disease | UNIV BORDEAUX (FR) | 2020-10-27 | — | — | US | disclosed |
| US-10632120-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-10632120-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| EP-1838321-A4 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF HIV INFECTION | UNIV EMORY (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1838320-A4 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL DISORDERS | UNIV EMORY (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1838321-A2 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF HIV INFECTION | EMORY UNIVERSITY (US) | 2007-10-03 | — | — | EP | disclosed |
| EP-1838320-A2 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL DISORDERS | EMORY UNIVERSITY (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
| US-20060264451-A1 | CXCR4 antagonists for the treatment of HIV infection | EMORY UNIVERSITY | 2006-11-23 | — | — | US | disclosed |
| WO-2006074428-A2 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL DISORDERS | EMORY UNIVERSITY (US) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006074426-A2 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF HIV INFECTION | EMORY UNIVERSITY (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401836-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | SHBG, ABAT, GLS | CXCR4 4766/4885FABP1 489/4885FABP6 19/4885 |
| US-20060264451-A1 | CXCR4 antagonists for the treatment of HIV infection | CXCR4, CXCL12, CCR5 | CXCR4 1/4885FABP1 1694/4885FABP6 1944/4885 |
| US-11285151-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | CXCR4 4766/4885FABP1 489/4885FABP6 19/4885 |
| US-10632120-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | CXCR4 4766/4885FABP1 489/4885FABP6 19/4885 |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | CXCR4, CXCL12, CXCR1 | CXCR4 1/4885FABP1 552/4885FABP6 741/4885 |
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | CXCR4 4766/4885FABP1 489/4885FABP6 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.